Stock Market & Financial Investment News

News Breaks October 24, 2012 06:28 EDT UTHR United Therapeutics downgraded to Underweight from Neutral at JPMorgan JPMorgan downgraded United Therapeutics following the FDA rejection of oral Remodulin. Price target lowered to $40 from $50. News For UTHR From The Last 14 Days Check below for free stories on UTHR the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 15, 2013 12:37 EDT UTHR United Therapeutics downgraded to Hold from Buy at Standpoint Research Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.